Wechselwirkungen · Anoro Ellipta (previously Anoro)
ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed · Abschnitt 4.5 · PDF-Seite 5
HOS-129128 · Präparat HOS-096681
Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers lacking CYP2D6 (poor metabolisers). No effect on umeclidinium AUC or Cmax was observed at a 8-fold higher dose. An approximately 1.3-fold increase in umeclidinium AUC was observed at 16-fold higher dose with no effect on umeclidinium Cmax. Based on the magnitude of these changes, no clinically relevant interaction is expected when umeclidinium/vilanterol is co-administered with CYP2D6 inhibitors or when administered to patients genetically deficient in CYP2D6 activity (poor metabolisers).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-31T09:00:00Z · SHA-256 55532081e38077e14b6448f7cc246b93ec49bd5a6fa1e010be00e4a9b8e25695 · Passage f6c369d28f972969233a684baf7bc94bb815e886cc4d2c8f3b928264ebe91570 · Zeichen 1506–2145 im Abschnitt